No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs

被引:9
|
作者
Rasmussen, M [1 ]
Poulsen, PH
Treiber, A
Delahaye, S
Tankisi, A
Cold, GE
Therkelsen, K
Gjedde, A
Astrup, J
机构
[1] Aarhus Univ Hosp, Dept Neuroanaesthesia, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Dept Neurosurg, DK-8000 Aarhus, Denmark
[3] Aarhus Univ Hosp, Positron Emiss Tomog Ctr, DK-8000 Aarhus C, Denmark
[4] Aalborg Gen Hosp, Dept Clin Chem, Aalborg, Denmark
[5] Actel Pharmaceut Ltd, Allschwil, Switzerland
关键词
bosentan; cerebral blood flow; cerebral metabolic rate of oxygen; endothelin; indomethacin; positron emission tomography;
D O I
10.1034/j.1399-6576.2003.00019.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: The mechanism behind indomethacin-induced cerebral vasoconstriction is incompletely understood. We tested the hypothesis that the mixed endothelin-1 receptor antagonist bosentan would modify or prevent indomethacin-induced reduction of CBF in the anaesthetized pig. Furthermore, we investigated the effect of bosentan on resting CBF and CMRO2. Methods: Twelve pigs were randomized in two groups of six, and received either bosentan and indomethacin (group 1), or placebo and indomethacin (group 2). Anaesthesia was induced with ketamine and midazolam and maintained with fentanyl, nitrous oxide and pancuronium. Baseline measurements of CBF and CMRO2 were performed before intravenous bolus injection of bosentan (10 mg/kg) or placebo (0.9% NaCl). The second CBF and CMRO2 measurement was performed 30 min after administration of bosentan/placebo. A 40-min infusion of indomethacin (0.05 mg/kg/min) was administered and the third CBF and CMRO2 measurement was performed 80 min after administration of bosentan/placebo. Independently, pharmacokinetic data of bosentan were generated in four pigs. Results: In group 1, baseline CBF was 55 +/- 7 ml/100 cm(3) /min. Administration of bosentan i.v. did not change CBF significantly. Indomethacin decreased CBF to 41 +/- 5 ml/100 cm(3)/min (P < 0.002). In group 2, baseline CBF was 54 +/- 10 ml/100 cm(3) /min. Placebo did not change CBF while indomethacin decreased CBF significantly to 41 +/- 5 ml/100 cm(3)/min (P < 0.002). No significant changes in CMRO2 were observed. In group 2, a significant increase in MABP was observed after administration of indomethacin. No change in MABP was observed in the bosentan-treated animals. Total plasma concentrations of bosentan at the time of the first and the second PET measurement were 3.9 and 1.4 mug/ml, respectively. The corresponding values for the pharmacologically active metabolite Ro 48-5033 were 1.2 and 0.4 mug/ml. Conclusion: These findings indicate that endothelin receptor stimulation is not involved in indomethacin-induced cerebral vasoconstriction or maintenance of cerebrovascular tone in the anaesthetized pig. However, our results suggest that the increase in MABP is mediated through endothelin receptors.
引用
收藏
页码:200 / 207
页数:8
相关论文
共 50 条
  • [1] INDOMETHACIN-INDUCED REDUCTION OF NEONATAL CEREBRAL BLOOD-FLOW AND OUTCOME AT 1 AND 2 YEARS
    DENOUDEN, L
    VANBEL, F
    WEDERFOORT, AH
    PEDIATRIC RESEARCH, 1990, 27 (04) : A203 - A203
  • [2] IS THERE A RELATIONSHIP BETWEEN INDOMETHACIN-INDUCED REDUCTION IN NEONATAL CEREBRAL BLOOD-FLOW VELOCITY AND PROSTAGLANDIN PRODUCTION
    VANBEL, F
    VANZOEREN, D
    HOUDKAMP, E
    BERGER, HM
    DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS, 1993, 20 (1-2): : 45 - 53
  • [3] THE ACTIONS OF BOSENTAN, AN ENDOTHELIN RECEPTOR ANTAGONIST, ON CEREBRAL ARTERIOLES IN-SITU
    PATEL, TR
    MCAULEY, MA
    MCCULLOCH, J
    BRITISH JOURNAL OF PHARMACOLOGY, 1994, 112 : U31 - U31
  • [4] Endothelin receptor antagonist bosentan improves microcirculatory blood flow in splanchnic organs in septic shock
    Krejci, V
    Hiltebrand, LB
    Erni, D
    Sigurdsson, GH
    CRITICAL CARE MEDICINE, 2003, 31 (01) : 203 - 210
  • [5] Indomethacin-induced reduction in neonatal piglet mesenteric blood flow is blunted by dopexamine
    Mero, KA
    Choe, EU
    Flint, LM
    Ferrara, JJ
    JOURNAL OF PEDIATRIC SURGERY, 1998, 33 (05) : 688 - 693
  • [6] THE EFFECT OF BOSENTAN, A NEW POTENT ENDOTHELIN RECEPTOR ANTAGONIST, ON THE PATHOGENESIS OF CEREBRAL VASOSPASM
    SHIGENO, T
    CLOZEL, M
    SAKAI, S
    SAITO, A
    GOTO, K
    NEUROSURGERY, 1995, 37 (01) : 87 - 90
  • [8] The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension
    Krum, H
    Viskoper, RJ
    Lacourciere, Y
    Budde, M
    Charlon, V
    NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (12): : 784 - 790
  • [9] Role of endothelin in the circulatory changes associated with small bowel strangulation obstruction in pigs: Effects of the endothelin receptor antagonist bosentan
    Fevang, J
    Ovrebo, K
    Myking, O
    Grong, K
    Svanes, K
    JOURNAL OF SURGICAL RESEARCH, 2001, 96 (02) : 224 - 232
  • [10] The preventive effect of a new endothelin receptor antagonist (ETRA) (Ro 48-5695) on indomethacin-induced acute gastropathy.
    Huang, JQ
    Padol, I
    Hunt, RH
    GASTROENTEROLOGY, 1997, 112 (04) : A153 - A153